Takeda Pharmaceutical Company Ltd
- Country
- π―π΅Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
A Study of TAK-861 for the Treatment of Narcolepsy Type 1
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 168
- Registration Number
- NCT06470828
- Locations
- πΊπΈ
Takeda Site 1, Columbia, South Carolina, United States
πΊπΈTakeda Site 42, Cleveland, Ohio, United States
πΊπΈTakeda Site 49, Danville, Pennsylvania, United States
A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A
- Conditions
- Acquired Hemophilia A
- Interventions
- Drug: Susoctocog Alfa (Genetical Recombination)
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Takeda
- Target Recruit Count
- 25
- Registration Number
- NCT06461533
- Locations
- π―π΅
Takeda selected site, Tokyo, Japan
A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis
- Conditions
- Pouchitis
- Interventions
- Drug: Concomitant Antibiotic Therapy
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 30
- Registration Number
- NCT06443502
- Locations
- π§πͺ
UZ Leuven, Leuven, Vlaams Brabant, Belgium
ππ·Klinika Za Djecje Bolesti Zagreb, Zagreb, Grad Zagreb, Croatia
π¨πΏFakultni nemocnice v Motole, Praha, Czechia
A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- Conditions
- Thrombotic Thrombocytopenic Purpura (TTP)
- Interventions
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 40
- Registration Number
- NCT06441578
- Locations
- π―π΅
Takeda selected site, Tokyo, Japan
A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 20
- Registration Number
- NCT06439342
- Locations
- π¨π³
Anhui Provincial Hospital(The First Affiliated Hospital of USTC), Hefei, Anhui, China
π¨π³Xinqiao Hospital Army Medical University, Chongqing, Chongqing, China
π¨π³Guangzhou First People's Hospital, Guangzhou, Guangdong, China
A Study on the Outcomes of Recombinant Von Willebrand Factor on Demand Treatment and Prevention and Treatment of Bleeding During and After Surgery in Adults With Inherited Von Willebrand Disease in the United Kingdom (UK)
- Conditions
- Von Willebrand Disease (VWD)
- Interventions
- Other: No Intervention
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Takeda
- Target Recruit Count
- 34
- Registration Number
- NCT06433778
- Locations
- π¬π§
Leeds Teaching Hospital, Leeds, United Kingdom
π¬π§Manchester University, Manchester, United Kingdom
π¬π§Imperial College Healthcare, London, United Kingdom
A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine
- Conditions
- Dravet Syndrome (DS)Lennox-Gastaut Syndrome (LGS)
- Interventions
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 45
- Registration Number
- NCT06422377
- Locations
- π©π°
Epilepsihospitalet Filadelfia, Dianalund, Zealand, Denmark
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Conditions
- Ulcerative ColitisCrohn's Disease
- Interventions
- Other: No Intervention
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Takeda
- Target Recruit Count
- 70
- Registration Number
- NCT06405087
A Study on Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS) in Children, Teenagers and Adults in Portugal
- Conditions
- Lennox-Gastaut Syndrome (LGS)Dravet Syndrome (DS)
- Interventions
- Other: No Intervention
- First Posted Date
- 2024-05-02
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 100
- Registration Number
- NCT06395792
A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 28
- Registration Number
- NCT06390995
- Locations
- π―π΅
Aichi Cancer Center, Nagoya, Aichi, Japan
π―π΅Jikei University Kashiwa Hospital, Kashiwa, Chiba, Japan
π―π΅National Cancer Center Hospital East, Kashiwa, Chiba, Japan